Report
No Data Yet
UnitedHealth Group posted $5.48 billion in Q2 net income as its medical care ratio dropped to 86.7%, driving a full-year adjusted EPS forecast of $19.50 to $20.00. "The year-over-year decrease was driven by benefit design and pricing discipline, member mix and medical cost management initiatives," the company said in its earnings statement. Revenue reached $112.03 billion, topping the $110.67 billion consensus estimate and edging past the $111.6 billion reported a year earlier. Net income of $6.04 per share compared with $3.74 per share in the year-ago quarter. The medical care ratio — the share of premium revenue spent on medical claims — improved 270 basis points from 89.4 percent in Q2 2025, marking the second consecutive quarter below 90 percent after hitting 91.5 percent in Q4 2025. The improved cost picture reflects UnitedHealth's exit from unprofitable Affordable Care Act and Medicare Advantage markets, which reduced total health plan membership to 48.5 million from 49.8 million at year-end 2025. The company's roughly $1.5 billion artificial intelligence program aims to further contain costs, even as rival Elevance Health reported a 89.7 percent benefit expense ratio for the same quarter. UnitedHealth's performance comes as the broader healthcare services sector stages a sharp rebound. Payers and payviders swung from a median year-to-date return of negative 21.7 percent at the end of Q1 to positive 31.1 percent, according to PitchBook data. The Centers for Medicare and Medicaid Services' final 2027 Medicare Advantage rate notice landed at an effective increase of approximately 5 percent, a sharp reversal from the near-flat 0.09 percent floated in January that had weighed on the sector. The guidance raise signals management expects the cost trend to hold through year-end. Investors will watch the Q3 earnings call for updated membership numbers and further detail on the AI cost-reduction program's impact on the medical care ratio. This article is for informational purposes only and does not constitute investment advice.
UnitedHealth Group plans to repurchase at least $5 billion of its shares in 2026, sending its stock up more than 5% in pre-market trading. The buyback plan was disclosed in a company statement on July 16, according to a report from Cailianshe. The $5 billion target compares with $5.545 billion in share repurchases in 2025 and $5 billion in 2021, according to company filings. UnitedHealth's average annual buyback has been about $6.9 billion. The buyback shows management's confidence in UnitedHealth's cash flow and financial position. Investors will watch the company's next earnings report for updates on capital allocation and any changes to its buyback authorization. UnitedHealth, the largest US health insurer by revenue, has consistently returned capital to shareholders through buybacks and dividends. The $5 billion commitment for 2026 represents a meaningful portion of expected free cash flow. The pre-market surge pushed UnitedHealth's stock higher, reflecting investor enthusiasm for the buyback news. The broader healthcare sector also benefited from the positive sentiment, with managed care peers such as Elevance Health and Cigna seeing modest gains in pre-market trading. The buyback plan reinforces UnitedHealth's commitment to shareholder returns. The company's next quarterly earnings report will provide further clarity on its capital allocation strategy and cash flow outlook. This article is for informational purposes only and does not constitute investment advice.
**UnitedHealth Group and Elevance Health report quarterly earnings on July 15 and 16, testing whether the health insurance sector's 28% year-to-date rally can withstand a second-quarter cost check.** UnitedHealth Group and Elevance Health report quarterly results this week, with the two largest US health insurers by market capitalization facing investor scrutiny on medical cost trends after a first quarter that rewarded disciplined pricing. Elevance Health kicks off the week on July 15, followed by UnitedHealth on July 16 and CVS Health on Aug. 5. The trio collectively covers more than 100 million members across commercial insurance, Medicare Advantage and Medicaid. "The first quarter showed that repricing is working, but the question is whether those margins hold into the back half of the year," said Sam Goldstein, healthcare analyst at Edgen. "The market is pricing in a beat for UnitedHealth, but Elevance has more to prove after its benefit ratio spiked in the fourth quarter." UnitedHealth enters the week with momentum. The Minnetonka, Minnesota-based insurer delivered first-quarter adjusted EPS of $7.23, beating the $6.60 consensus by 9.55 percent, while its medical care ratio improved 90 basis points to 83.9 percent. Operating cash flow jumped 63.34 percent to $8.9 billion. Management raised full-year 2026 adjusted EPS guidance to above $18.25 from a prior above-$17.75 target. Prediction market Polymarket assigns a 71 percent probability of a second-quarter beat. Elevance Health faces a higher bar. The Indianapolis-based insurer is expected to report EPS of $6.18, down 30.1 percent from a year earlier, on revenue of $48.45 billion, a 2 percent decline. Its fourth-quarter 2025 benefit expense ratio hit 93.5 percent, meaning the company paid out 93.5 cents of every premium dollar on medical claims, swinging its Health Benefits segment to a loss. The Zacks Earnings ESP, which measures the gap between the most recent analyst estimate and the consensus, stands at negative 0.42 percent for Elevance, suggesting analysts have turned slightly more bearish ahead of the print. **What the results mean for the sector** The earnings come at a pivotal moment for managed care stocks. The S&P 500 Managed Health Care index has gained roughly 28 percent year to date, outpacing the broader S&P 500's 10 percent advance, as investors bet that 2025's cost pressures were a one-time event driven by elevated outpatient utilization and Medicare Advantage rate resets. Humana's experience shows the risk of getting it wrong. The Louisville-based insurer guided full-year 2026 adjusted EPS to at least $9.00, down from $17.14 in fiscal 2025 — a 47 percent decline driven by Star Ratings damage that reduced Medicare Advantage quality bonus payments. UnitedHealth, by contrast, carries no such Star Ratings overhang and operates with the scale advantage of a $388.9 billion market cap. For UnitedHealth, the key metric is the medical care ratio. At 83.9 percent in the first quarter, it sits well below Elevance's fourth-quarter 93.5 percent and Humana's elevated levels. The company plans roughly $8.0 billion in dividends and $2.5 billion in buybacks in 2026, with a $2 billion buyback tranche completed by the end of the second quarter. The stock's 2.15 percent dividend yield on an $8.84 annual payout offers income support. For Elevance, the focus will be on whether the benefit expense ratio has improved from the fourth-quarter peak and whether management can stabilize the Health Benefits segment. The company has beaten consensus EPS estimates in three of the past four quarters, including a 17.79 percent surprise in the most recent reported period. The results will set the tone for the sector heading into the second half of 2026. A clean print from both insurers could extend the rally; a miss — particularly on medical cost trends — could trigger a sector-wide reassessment of margin expectations. This article is for informational purposes only and does not constitute investment advice.
UnitedHealth Group Inc. heads into its July 16 earnings report with the strongest setup in managed care, carrying a 71% probability of beating Q2 consensus, according to prediction market data. "The repricing thesis showed up once in Q1 and is set up to repeat next Thursday," Joel South, an analyst covering large-cap healthcare at 24/7 Wall St., said. UnitedHealth delivered adjusted EPS of $7.23 in Q1 2026 versus a $6.60 consensus estimate, a 9.55% beat, while its medical care ratio improved 90 basis points to 83.9%. Operating cash flow jumped to $8.9 billion, up 63% year over year. Management raised full-year 2026 adjusted EPS guidance to greater than $18.25, up from the prior above-$17.75 mark. The options market is pricing a 6.1% share move on July 16, according to Bloomberg data. The stock has exceeded the implied move in four of the past eight earnings announcements, including a 10.5% swing on April 21 versus a 5.4% implied move. Shares last traded around $430.72 on July 9, up 28% year to date and 42% over the past 12 months, recovering from a seven-year low of $234.60 in August 2025. Analysts are overwhelmingly bullish, with 23 buy or strong-buy ratings against a single sell. The consensus price target stands at $418.04, implying a forward P/E of roughly 23 times. The Zacks consensus estimate calls for Q2 EPS of $4.84, an 18.6% increase from the prior-year quarter, on revenue of $110.05 billion. UnitedHealth's competitive positioning has widened against peers. Humana is guiding FY 2026 adjusted EPS to at least $9.00, down 47% from $17.14 in FY 2025, driven by Star Ratings damage UnitedHealth does not carry. Elevance Health posted a benefit expense ratio of 93.5% in Q4 2025, swinging its Health Benefits segment to a loss. UnitedHealth's 83.9% medical cost ratio places it in a different tier, and its $388.9 billion market cap reflects the scale advantage. The company plans roughly $8.0 billion in dividends and $2.5 billion in buybacks in 2026, with a $2 billion buyback tranche completed by the end of Q2. The annual dividend of $8.84 per share yields 2.15%. The Q1 beat produced a 6.96% same-day gain and a 10.54% 30-day return, outperforming both the S&P 500 and the Nasdaq 100. A similar outcome on July 16 would reinforce the repricing narrative that has driven the stock's 57% rally since late March. Investors will watch for updated medical cost trends and any changes to the full-year guidance range. This article is for informational purposes only and does not constitute investment advice.
More than 40 House Democrats led by Texas Representative Lloyd Doggett introduced legislation Wednesday that would cut payments to private Medicare Advantage plans, targeting what they call billions of dollars in annual overpayments to insurers including UnitedHealth Group Inc. and Humana Inc. "The unjustified, costly advantage private Medicare Advantage insurers receive must be ended to save taxpayers and end the disadvantage for Traditional Medicare," Doggett said in a statement announcing the Save MEDICARE Act of 2026 (H.R. 9544). The bill would exclude certain diagnosis codes identified as vulnerable to overcoding from payment calculations, prevent insurers from using diagnoses generated through chart reviews and health-risk assessments when calculating risk-adjusted payments, and accelerate Risk Adjustment Data Validation audits to recover improper payments. It would also require Medicare Advantage and Part D plans to reimburse the Department of Veterans Affairs for covered services provided to veterans and give states greater enforcement authority over Medicare Advantage requirements. More than 67 million Americans are enrolled in Medicare, with private Medicare Advantage plans now covering roughly half of all beneficiaries — up from about 30 percent a decade ago. Lawmakers say excessive payments to Medicare Advantage insurers could cost taxpayers trillions of dollars over the coming decade if left unchecked. **The Overpayment Debate** The Congressional Budget Office has not yet scored the bill, but the Medicare Payment Advisory Commission has repeatedly found that Medicare Advantage plans cost the government more per beneficiary than traditional Medicare. In 2023, MedPAC estimated the government paid Medicare Advantage plans 104 percent of what it would have spent on comparable beneficiaries in traditional Medicare — a 4 percent premium that translates to billions annually. Private insurers argue the comparison is misleading because Medicare Advantage plans provide additional benefits including dental, vision and hearing coverage that traditional Medicare does not. The industry has pushed back against what it calls "cuts to benefits seniors rely on." The legislation faces a difficult path through a Republican-controlled Congress. Republicans have generally favored expanding private plan options rather than tightening oversight, though some have expressed concern about Medicare's long-term solvency. The Medicare trust fund is projected to become insolvent by the early 2030s. **What It Means for Beneficiaries** The immediate effect on seniors would likely be indirect. Reducing overpayments could strengthen Medicare's finances, potentially leading to better benefits or lower out-of-pocket costs in traditional Medicare over time. "For beneficiaries, the bill would not immediately take away Medicare Advantage plans, but it could reduce insurer profits and potentially redirect savings toward stronger traditional Medicare benefits," said Alex Beene, a financial literacy instructor at the University of Tennessee at Martin. For the roughly 33 million Americans enrolled in Medicare Advantage plans, insurers could respond to lower federal payments by reducing supplemental benefits or adjusting premiums. Kevin Thompson, CEO of 9i Capital Group, said the bill could "lower costs within Medicare Advantage, better align outcomes with traditional Medicare, and potentially help the overall Medicare system remain solvent longer term." The bill has been referred to the House Ways and Means Committee. No hearings have been scheduled. This article is for informational purposes only and does not constitute investment advice.
UnitedHealth Group Inc. expects net margin to improve to about 3.6% in 2026 from 2.7% a year earlier, prioritizing profitability over the rapid enrollment growth that defined its prior strategy. "The shift reflects a recognition that the Medicare Advantage market no longer rewards scale without underwriting discipline," said Ana Gupte, senior healthcare analyst at Leerink Partners. "UnitedHealth is repricing plans and exiting unprofitable markets to protect returns." In the first quarter, adjusted earnings topped consensus expectations while the medical care ratio improved 90 basis points year over year to 83.9%, showing better control over medical costs. The company also raised its full-year adjusted EPS outlook. The MCR of 83.9% means UnitedHealth paid about 84 cents of every premium dollar on medical claims, down from nearly 85 cents in the prior-year period. The strategic reset carries risk. Slowing enrollment growth could disappoint investors who bought the stock for its expansion story, while competitors Cigna Group and Elevance Health Inc. pursue similar margin-focused strategies. The question is whether UnitedHealth can sustain earnings momentum without the membership gains that once drove its premium revenue. **Optum's Role in the Turnaround** UnitedHealth's turnaround is not solely about cost cuts. Optum, its health services division, remains the primary growth engine, expanding in value-based care, specialty pharmacy and technology-enabled services. These businesses carry higher margins than traditional insurance and provide a buffer against medical cost inflation in the Medicare Advantage book. The company is also restructuring its pharmacy benefit management business, introducing a transparent fee-based pricing model that replaces the traditional rebate-driven system. The move aims to strengthen client relationships and reduce regulatory risk as Washington scrutinizes PBM practices. **Peers Face Similar Pressures** UnitedHealth is not alone in adapting to a tougher environment. Cigna Group is leaning on its Evernorth health services unit, which includes specialty pharmacy and AI-powered care solutions. The recent launch of Pharmacy Forward shows Cigna's focus on simplifying specialty drug management while supporting earnings growth. Elevance Health, meanwhile, continues to invest in its Carelon platform, expanding value-based care and integrated health services. The company has emphasized disciplined pricing and medical cost management as industry-wide headwinds persist. For all three insurers, the challenge is the same: maintain margins without sacrificing the membership base that generates premium revenue. UnitedHealth's early results suggest the strategy is gaining traction, but the full test will come as 2027 Medicare Advantage bids are submitted later this year. This article is for informational purposes only and does not constitute investment advice.
UnitedHealth Group will cover Guardant Health Inc.'s Shield blood test for colorectal cancer screening, unlocking 100 million covered lives and making it the most broadly accessible blood-based CRC screening option in the US. "Expanding Shield coverage through the nation's largest commercial health insurer to the 45-plus population marks a critical milestone in our commercial expansion," AmirAli Talasaz, co-chief executive officer at Guardant Health, said. Shield detects DNA methylation alterations in cell-free DNA from a routine blood draw. In a New England Journal of Medicine study of more than 10,000 patients, the test demonstrated 83.1% sensitivity for colorectal cancer and 89.6% specificity. It is the only FDA-approved blood-based CRC screening tool included in both American Cancer Society and National Comprehensive Cancer Network guidelines. GH shares surged as much as 10% Wednesday to trade at their highest level in more than five years. The stock has gained about 61% year to date and more than tripled over the past 12 months, outpacing the S&P 500. BTIG called the UnitedHealth decision a "huge" derisking event for Guardant's screening business and raised its price target to $190 from $150, implying about 27% upside from Tuesday's close. UnitedHealth Group, the largest US commercial insurer with about 40 million members across employer plans, Medicare Advantage and supplemental Medicare coverage, will apply the updated policy starting Aug. 1. The coverage applies to eligible policyholders aged 45 or older at average risk of colorectal cancer — a population that has seen rising incidence rates in recent years. Colorectal cancer is now the leading cause of cancer death for Americans under 50, according to Scientific American. The decision pressures other major insurers including Anthem, Aetna and Cigna to follow suit, analysts said. Citi described the move as "another positive catalyst" for Guardant, noting it "unlocks a new cohort of volumes and should drive significant average selling price benefits." The coverage arrived roughly one to two years ahead of BTIG's expectations, the firm said. Guardant's Shield test competes with Exact Sciences Corp.'s Cologuard, a stool-based DNA test, and traditional colonoscopy, the gold standard. Cologuard generated about $2.3 billion in revenue for Exact Sciences in 2025, according to company filings. Shield's blood-based approach eliminates the need for stool collection or bowel preparation, potentially expanding the addressable screening population beyond the roughly 60% of eligible Americans who are currently up to date with CRC screening. GH shares, trading at elevated multiples after the year's rally, still have room to run if additional commercial insurers adopt similar coverage policies, analysts said. The company's screening business now has a clearer path to revenue growth, with the UnitedHealth decision serving as a potential template for national coverage determinations. This article is for informational purposes only and does not constitute investment advice.
**UnitedHealth Group has staged an 80% rebound from its 2025 low, but the easy money may already be made.** UnitedHealth Group's medical care ratio improved to 83.9% in the first quarter, down from 84.8% a year earlier, as the insurer prioritized margin recovery over membership growth. "The historic disciplines and innovations of UnitedHealthcare are rounding back into place," Chief Executive Officer Stephen Hemsley said on the company's first-quarter earnings call. Adjusted earnings per share of $7.23 beat consensus estimates by about 10%, while revenue rose just 2% year over year to $111.7 billion — a sharp slowdown from the 12% growth the company posted for all of 2025. Management raised its full-year adjusted EPS guidance to more than $18.25, and the company generated $8.9 billion in operating cash flow during the quarter. The recovery has pushed shares to about $427, up roughly 80% from the 2025 low of $234.60. But with the stock now trading at about 23 times forward earnings — up from 13 times at the trough — and a Department of Justice investigation into Medicare Advantage billing practices unresolved, the risk-reward calculus has shifted. **Margin recovery comes at a cost** UnitedHealthcare, the company's insurance arm, shed 965,000 Medicare Advantage members in the first quarter alone and plans to cut 2.3 million to 2.8 million more through exits of unprofitable contracts. The trade-off is visible in the top line: revenue growth slowed to 2% as the company accepted membership attrition to repair its medical cost ratio. The improvement in the medical care ratio was driven by a mix of pricing discipline, tighter cost management and favorable reserve development. That last factor, which means past claims came in lower than the company had set aside for, is not a tailwind the company can rely on every quarter. **Two clouds that won't lift** The first is legal. UnitedHealth has disclosed it is responding to both criminal and civil DOJ investigations into how it bills the government for Medicare Advantage members. The probe targets the way insurers document patient diagnoses to set federal reimbursement — a practice at the heart of the Medicare Advantage business model. A federal Office of Inspector General report published June 12 found that UnitedHealth's post-hospital care denial rates ranged from 51 percent to 80 percent across its Medicare Advantage plans, well above peers. Fairview Health Services said the same week it would stop accepting UnitedHealthcare Medicare Advantage in 2027, affecting more than 11,000 patients. The second is valuation. At 23 times forward earnings, the stock has already repriced much of the recovery story. Two of the most closely watched capital allocators — Warren Buffett's Berkshire Hathaway and David Tepper's Appaloosa Management — both exited or reduced their UnitedHealth positions in the first quarter. Preliminary 2027 Medicare Advantage rate announcements came in below expectations, adding further pressure to a business model already under regulatory scrutiny. For shares to deliver further upside, the company will need sustained margin improvement, stabilization in membership trends and a favorable resolution to the DOJ probe — none of which is guaranteed. This article is for informational purposes only and does not constitute investment advice.
**After losing more than half their market value, the three largest US health insurers have staged a sharp recovery as medical costs stabilize and Washington eases the pressure.** UnitedHealth Group, Humana and CVS Health have rebounded 25% to 45% this year as easing medical costs and a more favorable Trump administration Medicare Advantage policy reversed a multi-year downturn that wiped out more than half their market value. "The worst is clearly behind the industry after a brutal repricing cycle," said Sam Goldstein, healthcare analyst at Edgen. "But the easy gains have been captured — further upside requires sustained cost discipline and continued government support." Humana surged 45% year-to-date, UnitedHealth gained 25% and CVS rose 29%, recovering from peak-to-trough losses exceeding 50% over the prior two years. The rebound followed aggressive plan repricing, exits from unprofitable markets, and a Trump administration rate increase exceeding 5% for 2026 with another favorable update for 2027. Hospital operators swung the other way: HCA Healthcare fell sharply from its March high and Tenet Healthcare slumped alongside as admission and emergency-room visit growth slowed sharply in the first quarter. The recovery has already repriced valuations. Humana trades at 31 times forward earnings, up from 14 times at its March trough, while UnitedHealth trades at 21 times versus 14 times earlier this year. CVS trades at 12.8 times, up from 10 times. Against 2029 earnings, Humana trades at roughly 12 times — a more reasonable bet on the business once the recovery has fully played out. For the rally to extend, investors need multiple quarters of tame cost trends and continued government easing. The risk-coding overhaul that would have hurt industry profits is widely seen as deferred rather than dead. ## Medicare Advantage denial rates draw scrutiny While the financial recovery has been swift, the operational practices that contributed to insurer profitability are facing renewed scrutiny. Two June reports from the HHS Office of Inspector General found that the three largest Medicare Advantage plans denied requests for long-term care hospital admissions at rates nearly double those of smaller peers. CVS Health denied 80% of such requests, Humana denied 72% and UnitedHealth denied 71%, compared with a 42% average for the other 16 plans evaluated. For inpatient rehabilitation facilities, UnitedHealth led with a 66% denial rate, followed by Humana at 54% and CVS at 51%. The high denial rates have drawn criticism from post-acute care associations, which are calling on Congress and CMS to overhaul prior authorization practices. Of the denials that were appealed, 95% were overturned in the enrollee's favor, suggesting many requests may have been inappropriately rejected initially. The National Association of Long Term Hospitals urged action rather than further study, saying "when access to medically necessary care is delayed or denied, patients face longer recoveries and increased complications." ## The seesaw swings back The economics of US healthcare resemble a seesaw, with insurers on one side and hospitals, physicians and drugmakers on the other. After years of elevated medical utilization that crushed insurer margins, the balance has shifted. Hospital admission and emergency-room visit growth slowed sharply in the first quarter, while growth in major drug categories has cooled. The rotation within healthcare tells the story: HCA is down sharply from its March high, while Tenet has slumped alongside it. For the millions of seniors enrolled in Medicare Advantage, the turnaround cuts both ways. The wave of plan exits that defined the past two enrollment cycles should ease. But as insurers get more disciplined, the era of ever-richer benefits that included perks such as vision and grocery allowances is over. The industry has stabilized and insurers are running leaner than before — enough to swing the seesaw back, but not enough to hold it there without sustained favorable conditions. This article is for informational purposes only and does not constitute investment advice.